1256 related articles for article (PubMed ID: 27304433)
41. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
[TBL] [Abstract][Full Text] [Related]
43. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
Ball S; Dellva MA; D'Souza DN; Marangell LB; Russell JM; Goldberger C
J Affect Disord; 2014; 167():215-23. PubMed ID: 24995890
[TBL] [Abstract][Full Text] [Related]
44. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
Liebowitz MR; Yeung PP; Entsuah R
J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
[TBL] [Abstract][Full Text] [Related]
45. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
[TBL] [Abstract][Full Text] [Related]
46. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.
McIntyre RS; Cucchiaro J; Pikalov A; Kroger H; Loebel A
J Clin Psychiatry; 2015 Apr; 76(4):398-405. PubMed ID: 25844756
[TBL] [Abstract][Full Text] [Related]
47. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.
Ravindran AV; Kennedy SH; O'Donovan MC; Fallu A; Camacho F; Binder CE
J Clin Psychiatry; 2008 Jan; 69(1):87-94. PubMed ID: 18312042
[TBL] [Abstract][Full Text] [Related]
48. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.
Pangallo B; Dellva MA; D'Souza DN; Essink B; Russell J; Goldberger C
J Psychiatr Res; 2011 Jun; 45(6):748-55. PubMed ID: 21511276
[TBL] [Abstract][Full Text] [Related]
49. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial.
McIntyre RS; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Rosenblat JD; Brietzke E; Soczynska JK; Cosgrove VE; Miller S; Fischer EG; Kramer NE; Dunlap K; Suppes T; Mansur RB
JAMA Psychiatry; 2019 Aug; 76(8):783-790. PubMed ID: 31066887
[TBL] [Abstract][Full Text] [Related]
51. Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
Ball SG; Ferguson MB; Martinez JM; Pangallo BA; Nery ES; Dellva MA; Sparks J; Zhang Q; Liu P; Bangs M; Goldberger C
J Clin Psychiatry; 2016 May; 77(5):635-42. PubMed ID: 27035159
[TBL] [Abstract][Full Text] [Related]
52. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.
Calabrese JR; Ketter TA; Youakim JM; Tiller JM; Yang R; Frye MA
J Clin Psychiatry; 2010 Oct; 71(10):1363-70. PubMed ID: 20673554
[TBL] [Abstract][Full Text] [Related]
53. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
54. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
Earley WR; Guo H; Németh G; Harsányi J; Thase ME
Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
[TBL] [Abstract][Full Text] [Related]
55. Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.
Youssef EA; Berry-Kravis E; Czech C; Hagerman RJ; Hessl D; Wong CY; Rabbia M; Deptula D; John A; Kinch R; Drewitt P; Lindemann L; Marcinowski M; Langland R; Horn C; Fontoura P; Santarelli L; Quiroz JA;
Neuropsychopharmacology; 2018 Feb; 43(3):503-512. PubMed ID: 28816242
[TBL] [Abstract][Full Text] [Related]
56. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
[TBL] [Abstract][Full Text] [Related]
57. Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.
Kato M; Shiosakai M; Kuwahara K; Iba K; Shimada Y; Saito M; Isogai Y; Sekine D; Aoki K; Koga N; Higuchi T
Psychiatry Clin Neurosci; 2024 Feb; 78(2):113-122. PubMed ID: 37933521
[TBL] [Abstract][Full Text] [Related]
58. Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study.
Ng CG; Boks MP; Roes KC; Zainal NZ; Sulaiman AH; Tan SB; de Wit NJ
Eur Neuropsychopharmacol; 2014 Apr; 24(4):491-8. PubMed ID: 24503279
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
[TBL] [Abstract][Full Text] [Related]
60. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV
J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
